GPBAR1 and Hepatic steatosis: FXR agonists repress bile acid synthesis and hepatic gluconeogenesis; decrease hepatic DAG by activating diacylglycerol kinases to ameliorate lipid-induced hepatic insulin resistance. BAR502, a dual FXR and GPBAR1 agonist, protects against hepatic steatosis, hepatic inflammation, and glucose intolerance caused by High Fat Diet